ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Tilray Brands Inc

Tilray Brands Inc (TLRY)

0.8946
-0.0382
(-4.10%)
Closed February 18 4:00PM
0.8979
0.0033
(0.37%)
After Hours: 7:59PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
0.500.390.410.390.40-0.05-11.36 %271872/18/2025
1.000.010.010.010.01-0.02-66.67 %9,0799,2182/18/2025
1.500.010.010.010.010.000.00 %11731,8442/18/2025
2.000.010.010.010.010.000.00 %79,7642/18/2025

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
0.500.010.010.010.010.000.00 %3652/18/2025
1.000.110.120.120.1150.0450.00 %1,2063,6812/18/2025
1.500.000.000.000.000.000.00 %00-
2.000.000.000.000.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EFOIEnergy Focus Inc
$ 2.6204
(103.13%)
72.78M
STAIScanTech AI Systems Inc
$ 3.52
(71.71%)
145.51M
KWEKWESST Micro Systems Inc
$ 0.7931
(69.83%)
238.56M
ADTXAditxt Inc
$ 0.1106
(58.00%)
927.86M
HCTIHealthcare Triangle Inc
$ 0.7137
(49.03%)
54M
INLFINLIF Limited
$ 3.40
(-79.18%)
12.76M
BPTHBio Path Holdings Inc
$ 0.208237
(-67.11%)
6.53M
RSLSReShape Lifesciences Inc
$ 1.09
(-53.22%)
6.9M
PTPIPetros Pharmaceuticals Inc
$ 0.1386
(-52.70%)
28.78M
LGMKLogicMark Inc
$ 0.2941
(-50.04%)
7.02M
ADTXAditxt Inc
$ 0.1106
(58.00%)
927.86M
INTCIntel Corporation
$ 27.39
(16.06%)
258.27M
KWEKWESST Micro Systems Inc
$ 0.7931
(69.83%)
238.56M
NVDANVIDIA Corporation
$ 139.40
(0.40%)
194.79M
PRPHProPhase Labs Inc
$ 0.425
(30.77%)
175.41M

TLRY Discussion

View Posts
tapioca tapioca 5 hours ago
Not much dry powder on hand so I almost sold TRUG, to get in here but held off. TRUG releases news AHs, and it’s up 50%. Christ what a game we play..
👍️0
nssrr5 nssrr5 6 hours ago
Well your gut feeling has been correct so far.
👍️0
tapioca tapioca 6 hours ago
Not much bid support, such weird trading with high volume .. it still looks like shorts are just destroying it. It should be a meme stock… sheeesh. This fractional trading, ugh.
Everytime I think about jumping in, I don’t ..lol.
👍️0
nssrr5 nssrr5 9 hours ago
I feel it's just pure manipulation at this point...
👍️0
tapioca tapioca 10 hours ago
You have to ask yourself who or what is selling at these levels… seems crazy
👍️0
nssrr5 nssrr5 12 hours ago
Praying this is the case but I will believe it when I see it. Maybe Baby Bear Eating RFK JR is crazy enough to get it done
👍️0
BottomBounce BottomBounce 12 hours ago
Trump Ally Who Lobbies For Marijuana Industry Predicts Rescheduling And Banking Will Get Done Under New Administration https://marijuanamoment.net/trump-ally-who-lobbies-for-marijuana-industry-predicts-rescheduling-and-banking-will-get-done-under-new-administration-but-not-legalization/ $TLRY $MJ $MSOS $TOKE
👍️0
nssrr5 nssrr5 1 day ago
I made a Killing in SNDL years ago when people were screaming they needed to do something to stay compliant as I kept gobbling up shares in the .40 and .50 range and then it ran over 4 bucks a share.

I will do the same here but this time when it runs there will be no retreat. When this rockets from these levels it will be because it will finally be Cannabis time. Decriminalization is coming at some point and Tilray has set itself up to be the most dominant Cannabis Company in the World IMHO. This is like buying a .com before the internet boom....

I could be wrong about everything I type but I 1000% believe it, regardless of what the DoomLoooooser's of the world have to say about it. Not talking about you my friend but the other poster I have on IGNORE LOL.

Good Luck to you Tapioca - anything down here is an absolute gift long term of course... Again all in my humble opinion.
👍 1
BottomBounce BottomBounce 3 days ago
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner's High Brewing Company, Happy Flower, and Fresh Hemp Foods brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada. $TLRY
👍 1
tapioca tapioca 4 days ago
Still looking for an entry. But I’m sure the company is going to have to bring this back above a buck, and stay there, to continue to be compliant with Nasdaq. There seems to be plenty of buying but is it the shorts holding it down? The volume is quite high.
👍 1
nssrr5 nssrr5 4 days ago
She was creeping up this morning pre-market but has seemed to settle back down. .90 held yesterday but who knows where this will bottom. I hope it was yesterday but time will tell. Good Luck Tapioca
👍️0
doomed doomed 5 days ago

Hawaii House Shelves Recreational Cannabis Bill in Stunning Reversal

Ben Stevens (Doomed)
FEBRUARY 13, 2025
Hawaii House Shelves Recreational Cannabis Bill in Stunning Reversal

Less than 48 hours after Hawaii lawmakers appeared poised to legalize recreational cannabis, the state’s House of Representatives unexpectedly slammed the brakes, shelving the measure until at least 2032.

The sudden procedural move on Thursday, led by Representative Chris Todd, stunned advocates and lawmakers alike, reigniting frustration over the state’s stalled cannabis reform efforts.

Last week, Business of Cannabis reported that House Bill 1246 (HB 1246), championed by Representative David Tarnas, cleared two key committees: the House Judiciary and Hawaiian Affairs Committee, chaired by Tarnas, and the House Agriculture and Food Systems Committee.

The bill proposed legalizing personal cannabis use for adults 21 and over starting in 2026 while also establishing a comprehensive regulatory framework under the Department of Commerce and Consumer Affairs.

It would also have seen the creation of a new state agency, the Hawaii Cannabis and Hemp Office, to oversee both medical and recreational cannabis, as well as hemp products. It would also impose a tax on cannabis sales, as seen throughout the US.

Despite gaining momentum earlier in the week, clearing two key committees with a 6-4 and 5-0 vote, respectively, Todd introduced a rare motion to recommit the bill to committee, effectively tabling it for the year. The motion passed via voice vote without public debate.

“On this particular bill, it became clear that we did not have enough support to pass the measure in this session,” Todd told Civil Beat following the vote.

The bill remains alive for the 2026 legislative session without needing to be reintroduced, and a separate Senate proposal, SB 1613, is still under consideration.
👍️0
doomed doomed 5 days ago
Good luck guys. You are in good hands with Grumpy Trumpy!

Business of Cannabis North America
Republican Senators Introduce Bill to Block Cannabis 280E Tax Relief Even if Cannabis Is Rescheduled

Ben Stevens (doomed)
FEBRUARY 13, 2025
As the cannabis rescheduling project hangs in the balance, two Republican senators are attempting to ensure that one of its core benefits would be made redundant, even if rescheduling is successful.

Aside from the potential of interstate trade and the official acknowledgement of cannabis’ medical uses, businesses across the US are primarily looking ahead to the tax benefits that will come with rescheduling.

Section 280E of the federal tax code currently prohibits businesses involved in trafficking Schedule I or II controlled substances from deducting ordinary business expenses, leading to significantly higher effective tax rates for cannabis businesses compared to other industries.

Figures from Whitney Economics suggest that the additional tax paid by US cannabis operators due to 280E is now over $2bn a year, including hundreds of millions of dollars for some of the largest companies.

However, a newly proposed bill from senators James Lankford and Pete Ricketts would indefinitely extend this tax burden.

Under the proposed legislation, any company involved in ‘trafficking marijuana’ would remain subject to 280E, unless cannabis is completely descheduled—a scenario that remains politically improbable in the near future.

Lankford, a long-time cannabis opponent, framed his bill as a safeguard against legitimizing the industry.

“Marijuana doesn’t make our families stronger, our streets safer, or our workplaces more productive,” he stated, adding.

The effort has been strongly backed by Smart Approaches to Marijuana (SAM), a prohibitionist advocacy group which has already proven a major hindrance to the rescheduling process.

SAM President Kevin Sabet hailed the bill as a way to prevent what he called $2.3 billion in ‘tax cuts’ for the cannabis industry, stating that ‘the federal government should not be in the business of giving tax relief to the federally addiction-for-profit marijuana industry.’

The bill has sparked sharp criticism from cannabis industry advocates, who argue that maintaining 280E restrictions will only benefit the illicit market by making legal cannabis less competitive.
👍️0
doomed doomed 5 days ago
Business of Cannabis North America
Trump’s DEA Revolving Door: 4th Administrator in as Many Months Rings Alarm Bells for Cannabis Industry
FEBRUARY 13, 2025
The fourth head of the Drug Enforcement Administration (DEA) in as many months has been given the green light by President Donald Trump, painting an even more worrying picture for the future of cannabis in the US.

Trump has now nominated anti-cannabis Terrance C. Cole as the next DEA administrator, less than a month after appointing long-time cannabis sceptic Derek S. Maltz as ‘acting administrator.’

While it’s not yet clear why Maltz was shunned so quickly, his replacement, a 30-year law enforcement veteran and former DEA official, has caused even more panic in the country’s cannabis community.

Cole has historically taken an even more hardline stance than his all-too-temporary predecessor, publishing numerous public posts claiming, among other things, that cannabis is ‘four times more dangerous’ than 30 years ago, that it leads to higher suicide risk, while advocating a #justsayno stance.

Before taking office, Cole must still be confirmed by the Senate, which could prove to be a contentious process given his hardline stance on cannabis and drug enforcement. If confirmed, he will inherit the rescheduling review, along with growing scrutiny over the DEA’s role in delaying administrative hearings on the proposal.

While this places the rescheduling process on even more dangerous territory, one analyst told Business of Cannabis that it could signal much more serious consequences for cannabis policy in the country.

Deborah Tharp, cannabis legal researcher and consultant, says that this gives legitimacy to the theory that the administration is attempting to push through Project 2025 regardless of public opinion, including a war on state-legal cannabis.

“Trump has hardcore prohibitionists in all the right places now. Time to start praying for miracles.”

However, she stipulates that his choices reveal a lack of cohesive policy, no surprise given the president’s tendency to change his position on key topics on a dime.

This has already been demonstrated in his picks for the head of the DEA. Matt Gaetz, Trump’s first selection for administrator, announced in November that he was withdrawing himself from the process as he dealt with a House of Ethics Committee investigation into sexual misconduct.

His next choice, Florida County Sheriff Chad Chronister, abruptly withdrew his nomination for the post just weeks later.

Chronister’s sudden exit was initially framed as a voluntary withdrawal, citing dedication to his constituents; however, Trump soon sought to correct this to his own narrative, stating: “He didn’t pull out. I pulled him out because I did not like what he said to my pastors and other supporters.”

With suspicions that the far-right think tank, The Heritage Foundation, is largely guiding this administration, Tharp fears the US is ‘going to get very, very regressive’ in the coming months and years.
👍️0
nssrr5 nssrr5 5 days ago
I sure hope so.....
👍️0
tapioca tapioca 5 days ago
Ha, he’s into the hard stuff…what a joke.
We could very well be seeing the bottom here..
👍️0
nssrr5 nssrr5 5 days ago
Maybe our new Baby Bear Eating US Health Secretary can do something for the Cannabis Sector like some believe. Not holding my breath...
👍️0
doomed doomed 5 days ago
I understand why Floridians would buy Tilray…
They got nothing to lose!
👍️0
doomed doomed 5 days ago
Americans are on meth and the rest are on fentanyl.
There is no money left for bunk 20$ grams after buying eggs.
Maga rules until inflation hits the peak.
👍️0
doomed doomed 5 days ago
Installing DEA Terrance Cole in charge of canna legalization makes it easy for Grumpy Trumpy…
Dude cannot be trusted. Besides maga/dea don’t want no druggies.😂🤣😂
👍️0
nssrr5 nssrr5 5 days ago
It really is just a guessing game LOL. I just keep averaging down as I am playing the long game here. Got my average down to 1.74 or somewhere in there. A long way back to even...
👍️0
tapioca tapioca 5 days ago
I was going to say that some got suckered into buying in the .96 range, but was also thinking no one knows where the bottom is either, and then it dropped to .90 and hit a new 52wk low again. lol. Tough to know where to jump back in.
👍️ 1
doomed doomed 6 days ago
Good call! It will rocket back.
👍️0
drumkids drumkids 6 days ago
Trending
👍️0
nssrr5 nssrr5 6 days ago
Went on and added - none of is know where the bottom is so I added here. We could get .80 or .70 but this could also rocket back over a dollar.... So over sold IMHO - good luck all.
👍️0
doomed doomed 6 days ago
Sales pitch for canna naive investers!
Purchase shares before price go down…🤣😂🤣
👍️0
doomed doomed 6 days ago
Forbes wants cannabis naive investors to purchase mores cannabis shares. 🤣😂

You are in business with agent Terrance Cole.

D.E.A. Is pushing for cannabis legalization.

You guys are GOLDEN.

You will be rich.
👍️0
doomed doomed 6 days ago

Trump taps career DEA official to lead agency, oversee marijuana rescheduling
Doomed
February 12, 2025

President Donald Trump’s choice to lead the U.S. Drug Enforcement Administration is Terrance Cole, a career anti-cannabis DEA official currently serving as a top law enforcement official in Virginia.

The appointment of a longtime DEA insider – which Trump announced midday Tuesday in a social media post – is not likely to boost hopes that the agency will resume the Biden administration-initiated marijuana rescheduling process.

A previous Trump pick to head the DEA, Chad Chronister, a Florida sheriff, abruptly withdrew his nomination for the post.

Cole served more than two decades in the DEA, retiring in 2020 as the acting regional director overseeing operations in Canada, Central America and Mexico.

Trump has said he supports marijuana rescheduling, but Cole’s resume does not suggest he may embrace cannabis reform.

Cole worked under Virginia’s anti-marijuana governor
after exiting the DEA, Cole joined Virginia Gov. Glenn Youngkin’s administration, where he served as the state secretary of public safety and homeland security.

Youngkin, who has repeatedly opposed adult-use marijuana sales in Virginia, praised Cole’s appointment.

“He will put the safety and security of Americans first as head of the DEA,” Youngkin said in a statement.

“It’s a great day to be an American and a bad day to be a drug dealer.”

If confirmed by the Senate, Cole would assume control of the paused marijuana rescheduling process.

Marijuana rescheduling process remains up in air.

Rescheduling has been on hold since January after pro-legalization “designated participants” in hearings before a DEA administrative law judge accused the DEA of bias.

Critics have accused the DEA of slow-walking the process and refusing to hear evidence from states, including Colorado, in support of the change.

Considering those designated participants’ appeal and resuming the process – or abandoning it – is solely up to the discretion of the DEA administrator.

The acting administrator, Derek Maltz, also a longtime DEA insider, has not moved to resume the rescheduling process.

Nor did he indicate any plans one way or the other.

Capitol Hill observers believe federal agencies such as the DEA as well as Republican lawmakers will pursue whatever marijuana policy the White House demands.

However, a Trump edict issued on Inauguration Day froze all changes to federal law pending review – and approval – by a department or agency chief appointed by the president.
👍️0
tapioca tapioca 6 days ago
With the 3 branches of government now in Republican control,, things do not look good for the cannabis sector, although ACB made a big move recently. There will be a bounce off the bottom eventually, IMO, and I’ll be watching.
👍️0
nssrr5 nssrr5 6 days ago
I feel the cannabis market thinks that Trump is full of bull hense how far they have all pulled back since he won the election. I hope the market is proved wrong by our elected king.
👍️0
BottomBounce BottomBounce 7 days ago
Trump has indicated he supports reclassifying marijuana under federal drug laws as well as bill to ease access to banking services for pot companies. https://www.forbes.com/sites/ajherrington/2024/09/09/trump-backs-federal-marijuana-rescheduling-and-cannabis-banking-bill/ $TLRY
👍️0
nssrr5 nssrr5 7 days ago
Yeah I am waiting a bit with morning myself. .80s seems like they will happen and maybe even mid 70s.
👍️0
BottomBounce BottomBounce 7 days ago
$TLRY is gaining money making millions on not just weed but alcohol. Higher Lows coming.
Total Cash (mrq) $280.06M
👍️0
BottomBounce BottomBounce 7 days ago
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner's High Brewing Company, Happy Flower, and Fresh Hemp Foods brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada. $TLRY
👍️0
tapioca tapioca 7 days ago
So tempted to buy down at these levels, but bid support doesn’t look so great at the moment. Eventually there’ll be a bottom, but just amazing to see this pps, as it continues to set new 52 week lows
👍️0
doomed doomed 7 days ago
Bag holder😂🤣😂🎯
👍️0
nssrr5 nssrr5 7 days ago
My buying Wednesday - gobble gobble gobble. Also when will one get a clue and realize you don't looooose until you choose to sell at a loss.
👍️0
doomed doomed 7 days ago
Dude is loosing more than just losing😂🤣😂
Maga are born loser.
They love to shoot themselves in the foot.🦶
They are proud!
👍️0
nssrr5 nssrr5 1 week ago
HAHA
👍️0
tapioca tapioca 1 week ago
It’s spelled loser, with one s, not “looser”, which is how your hat is if your head shrinks
👍️0
doomed doomed 1 week ago
Nssrr5 is a professional bag holder!
Expert money looser.😂
👍️0
doomed doomed 1 week ago
Home / Finance
GOP senators’ bill would keep 280E for cannabis operators permanently intact
Doomed
February, 11 2025
SHARE

Two Republican U.S. senators have introduced a bill that would continue to ban federal tax deductions for the cannabis industry – regardless of whether marijuana is rescheduled.

According to Law360, James Lankford of Oklahoma and Pete Ricketts of Nebraska introduced the “No Deductions for Marijuana Businesses Act,” which would essentially kill any substantive tax breaks operators hoped to receive if marijuana status were downgraded from Schedule 1 to Schedule 3 of the Controlled Substance Act.

Under Internal Revenue Code Section 280E, cannabis operators are prohibited from deducting typical business expenses, such as payroll and marketing, on federal tax returns.

So, in that respect, the senators’ proposal would not change the federal government’s ongoing policy stance regarding 280E, a provision that has wiped more than $1 billion from the balance sheet of marijuana companies nationwide.

Some tax experts expressed doubts the bill would advance, given the widespread popularity of marijuana reform, Law360 reported.

In January, the U.S. Drug Enforcement Administration’s the chief administrative law judge canceled the marijuana rescheduling process indefinitely amid accusations the agency is deliberately corrupting the hearing.

In August 2023, federal health regulators under former President Joe Biden recommended rescheduling marijuana.

👍️0
nssrr5 nssrr5 1 week ago
Yeah we all knew it was coming for the last few months. But there is no freaking way this will be delisted. Its a billion dollar company that has enough cash on hand right now to be valued at 4 dollars. Shorts are in control unit cannabis is decriminalized and once that happens this will be 100 plus dollar stock. AIMHO

Irwin has had to now play the long game which he is doing with beer - the man is a genius...

Good Luck and I am adding all I can at these stupid levels.
👍️0
tapioca tapioca 1 week ago
Did you ever think it’d be under a buck?
Anything is possible, but a r/s can always bring them back to compliance if it ever got to that point. But I agree, I don’t think they’ll get delisted.
👍️0
nssrr5 nssrr5 1 week ago
They will never be delisted - no reason to spread that fear
👍️0
KILLAZILLA KILLAZILLA 1 week ago
Under $1, as predicted....
👍️0
tapioca tapioca 1 week ago
I wonder when they’re up for Nasdaq review.
👍️0
nssrr5 nssrr5 1 week ago
That is the million dollar question
👍️0
tapioca tapioca 1 week ago
Keeps dropping and not much buying even at these prices. Officially a penny stock. How low will it go.
👍️0
doomed doomed 1 week ago

Claims of marijuana testing lab fraud hit New York’s $1 billion adult-use market
Chris Roberts, Reporter
February 10, 2025

Familiar allegations of marijuana testing lab fraud – including vape oil cartridges with “certified” total cannabinoids of more than 100% – are now roiling the adult-use market in New York.

Accusations that labs are inflating THC potency to satisfy clients – and potentially manipulating data in tests meant to ensure consumer safety – echo similar complaints made across the country.

But they hit New York at a sensitive time.

Critics say the lab-fraud problem threatens to undermine consumer confidence just as recreational cannabis sales in New York eclipsed $1 billion for the first time after a rocky start.

Making the problem worse, according to two lab operators in New York, is that regulators aren’t taking the problem seriously.

‘The last thing NY cannabis needs right now’
In a December letter to the state Office of Cannabis Management (OCM), representatives from two of the state’s 16 testing labs outlined what they said are “serious problems.”

The problems included cannabis products with inflated THC potency, as well as vape oil cartridges with impossible cannabinoid profiles.

“If these issues remain unaddressed, we fear that unethical and unsafe lab results will become the norm, mirroring situations seen in other states and Canada,” Aaron Riley, the CEO of Orlando, Florida-based Certified Testing and Data, and Edward Lukaszek, the CEO of Biotrax Testing Laboratory in Buffalo, told the OCM in a Dec. 17 letter obtained Doomed.

They added that “no enforcement on this matter will only hamper the program for years to come.”

“We respectfully request that the OCM enact immediate recalls to begin dealing with these issues,” their letter continued.

“There is no place for such behavior in New York’s cannabis industry. It is leading to an erosion of trust – the last thing NY cannabis needs right now.”

But, as Riley and Williams Nichols, lead technical director at Biotrax, regulators are brushing off their concerns.

Lab officials are also months overdue in releasing data sets that could paint a fuller picture of the situation, they claimed.

In other states, anonymized testing data has revealed patterns that suggest data manipulation.

That would track with what some industry players believe is a deliberate effort to pump results to please clients.

Meanwhile, Nic Fera, a part-owner of Amsterdam, New York, cultivator Goldfinch Flora and board member of the Cannabis Farmers Alliance, claimed to have been approached by a salesperson from a licensed lab who offered a guarantee of high-potency test results – for a price.

“It’s a crisis for sure,” Fera told MJBizDaily.

Marijuana regulators’ actions unclear
In response to a request for comment, an OCM spokesperson said the agency “does not comment on open investigations, nor does it disclose actions taken against a licensee or permittee to a third party.”

In a Dec. 20 response to Lukaszek and Riley, state cannabis officials insisted they are taking “these concerns seriously and (are) committed to protecting public health and safety.”

“I can assure you that OCM is investigating the concerns you provided and will act in accordance with its regulatory protocols, should any allegations of potency inflation be substantiated,” wrote Nicole Rosa, the executive deputy director of the agency’s Office of Health and Scientific Affairs.

Rosa also wrote that whatever action OCM might be taking is confidential.

“OCM does not comment on open investigations, nor does it disclose actions taken against a licensee or permittee to another licensee or permittee, including to the complainant,” she wrote, in part.

“While the information you shared is much appreciated as we work to investigate concerns regarding potency inflation, OCM cannot recall products or impose disciplinary action upon licensees based solely upon the information you presented.”

Blowing the whistle
In their letter, Biotrax’s Lukaszek and Certified Testing’s Riley claim to “have received customer complaints regarding pesticide contamination, excessive micro reruns and false COAs (certificates of analysis)” produced by three competing labs.

Those labs are also “consistently reporting products with tested values beyond what other labs have found,” the letter claimed.

The lab officials also claimed in their letter to “have performed off shelf testing on various products proving that these results are dangerously inflated and misleading consumers.”

“Based on our findings, there is a pattern in the data which illustrates that these labs are likely inflating every test they complete.”

According to the letter, Certified Testing and Biotrax tested flower that a competitor certified at more than 30%.

Their tests found THC content to be in the teens.

The letter also identifies what it claims are several dozen examples of vaporizer oil cartridges with “certified” cannabinoid profiles of at or near 100%.

“A fifth grader can tell you that’s not right,” Riley told MJBizDaily.

How high is too high?
Such lab results are not meant to be exact.

State law allows a “potency variance” of 85%-115% in adult-use products, according to guidelines updated last summer.

However, even total cannabinoid percentages in excess of 90% are questionable.

That’s because vape oil generally contains terpenes for flavor and other compounds, such as “thinning agents,” that allow the product to be vaporized, according to published research.

In a 2021 study of 12 vape oil cartridges obtained from legal stores conducted by the California Department of Public Health, average total THC content rarely exceeded 70%.

In an review of vaporizer products on New York cannabis store menus, advertised THC contents in excess of 90% was common.

Both the wide potency variance and what they claimed is lax enforcement of mislabeled potency threaten to render lab results meaningless, Riley said.

Familiar lab-testing problem with state solution
According to some critics, similar dynamics are unfolding in other states.

In Massachusetts, one lab also active in New York, MCR Labs, sued some of its competitors in state court after it uncovered what it claimed to be a widespread pattern of potency inflation and data manipulation that allowed product tainted by mold or pesticides to be cleared for sale.

At the same time, most observers agree that best practices involve aggressive state oversight.

In other states, such as California and Colorado, state reference laboratories obtain product from marijuana store shelves for independent testing.

When products are found to have inflated potency or to be contaminated with pesticides or mold, the state regulators then issue a recall.

Recalls in California increased significantly – and some labs went out of business – after stricter regulations were imposed, including a more rigorous formula for determining total THC.

But New York has yet to publicize any recalls or reference testing.

An OCM spokesperson said in September that as of then, reference testing “has not been targeted at validating the reliability of permitted laboratory results.”
👍️0